[
    [
        {
            "time": "",
            "original_text": "丽珠试剂分拆上市冲击千亿蓝海、CRO第四家A+H企业将现……上市药企资本变局不断",
            "features": {
                "keywords": [
                    "丽珠试剂",
                    "分拆上市",
                    "CRO",
                    "A+H企业",
                    "资本变局"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "丽珠试剂分拆上市冲击千亿蓝海、CRO第四家A+H企业将现……上市药企资本变局不断",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智通AH统计|10月20日",
            "features": {
                "keywords": [
                    "AH统计"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智通AH统计|10月20日",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药企行贿案密集曝光，政策组合拳能斩断灰色利益链条吗？",
            "features": {
                "keywords": [
                    "药企",
                    "行贿案",
                    "政策组合拳",
                    "灰色利益链条"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药企行贿案密集曝光，政策组合拳能斩断灰色利益链条吗？",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药企行贿案密集曝光！灰色利益链还有多少生存空间？ 其他违规处罚",
            "features": {
                "keywords": [
                    "药企",
                    "行贿案",
                    "灰色利益链",
                    "违规处罚"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药企行贿案密集曝光！灰色利益链还有多少生存空间？ 其他违规处罚",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药企行贿案密集曝光：有院内人员收上千万回扣 其他违规处罚",
            "features": {
                "keywords": [
                    "药企",
                    "行贿案",
                    "回扣",
                    "违规处罚"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药企行贿案密集曝光：有院内人员收上千万回扣 其他违规处罚",
                "Correlation": 7,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]